Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human dose-escalation study of BI 764532 in DLL3-positive small cell lung carcinoma and other neuroendocrine neoplasms
jRCT2080225308Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of obrixtamig in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine carcinoma (NEC) and 1 more, sponsored by Boehringer Ingelheim. Started Aug 2020; status: suspended.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma (NEC)small cell carcinoma (SCC)
Beyond the preview
Go deeper on jRCT2080225308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225308.